Clinical trials: Primary CNS Lymphoma (PCNSL)
Primary CNS Lymphoma
Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Consolidation treatment for Primary Central Nervous System Diffuse Large B cell Lymphoma(PCNSL)patients remains to be defined.Here we designed a tolerated treatment of HDMTX plus Temozolomide,followed by consolidation with…
- Trial name
- NCT02934204
- Testing
- methotrexate, temozolomide
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Guangdong Provincial People's Hospital
Primary Central Nervous System Hodgkin Lymphoma
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
This phase II trial is evaluating the efficacy and side effect of orelabrutinib, sintilimab and temozolomide as possible treatments for relapsed or refractory central nervous system lymphoma.
- Trial name
- NCT04961515
- Testing
- Orelabrutinib, Sintilimab, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lymphoma
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00598169
- Testing
- rituximab, bortezomib, carboplatin
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- AIDS Malignancy Consortium
Anxiety Disorder, Cancer Survivor
Quality of Life in Younger Leukemia and Lymphoma Survivors
RATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best treatment.
- Conditions
- Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia
- Trial name
- NCT00956475
- Testing
- telephone-based intervention, questionnaire administration, assessment of therapy complications
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Primary Central Nervous System Lymphoma
Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
In summary, there is a high medical need for patients suffering from recurrent/progressive PCNSL. Targeting the PD-1 pathway may represent a very promising novel approach for the treatment of these patients.
- Trial name
- NCT02779101
- Testing
- pembrolizumab
- Where
- Austria
- Volunteers
- 21 people
- Sponsor
- Prof. Dr. Matthias Preusser
Central Nervous System Lymphoma
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
The purpose of this research study is to determine the safety of the study drug pemetrexed, and the highest dose of this drug that can be given to people safely.
- Trial name
- NCT00916630
- Testing
- pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Primary Central Nervous System Lymphoma (PCNSL)
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
- Trial name
- NCT04688151
- Testing
- Rituximab
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- National Health Research Institutes, Taiwan
Lymphoma
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00082836
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Primary Central Nervous System Lymphoma
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT02836158
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
Primary Central Nervous System Lymphoma
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival.
- Trial name
- OptiMATe (NCT04931368)
- Testing
- Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix, Control intervention: four courses of MATRix
- Where
- Germany
- Volunteers
- 331 people
- Sponsor
- Klinikum Stuttgart